The Firm Practices Insights & Assignments People Career Sustainability Contact

We use cookies

Moalem Weitemeyer uses cookies, including cookies from third parties, needed to make the website work and to enhance the user experience. Cookies are also used to detect inexpediencies and to examine your interactions with our website. Read more about how we use cookies and take care of your data here

Necessary/functional

Statistical

Back to Insights & Assignments

14 January 2021

Moalem Weitemeyer assisted in a Series B Financing in Danish clinical-stage biotech company

Moalem Weitemeyer assisted global healthcare and life science investment firms Vivo Capital (US), RA Capital Management, L.P. (US), Samsara BioCapital (US), and Eir Ventures (SE/DK) in connection with their participation in the EUR 127 million (USD 155 million) Series B Financing in Danish clinical-stage biotech company IO Biotech ApS. The investment round was led by HBM Healthcare Investments and several other new and existing shareholders participated too.

Click here to see the press release.